• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: A focused update
【24h】

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: A focused update

机译：造血移植受者巨细胞病毒感染的治疗策略：重点更新

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality in immunocompromised patients, particularly following allogeneic haematopoietic transplantation. One of the principal factors leading to this increased risk is the loss of T-cell immunity.Areas covered: In a recent review, we assessed the treatment strategies for prophylaxis and pre-emptive treatment of CMV, particularly where relevant to the high-risk patient populations following allogeneic haematopoietic transplantation. This review is a focused update to our previous article and presents a more detailed analysis of the developments in drugs, vaccines and adoptive T-cell therapies since that time. Relevant studies were selected from PubMed and clinicaltrials.gov. The search terms include allogeneic transplant, cytomegalovirus, multidrug-resistant virus and adoptive T-cell therapy.Expert opinion: The current randomised controlled studies evaluating pharmacological agents for CMV should inform as to whether these provide significant clinical benefits. Adoptive cell therapy provides a more physiological approach to the problem of lack of CMV-specific immunity. Recent reports add to the evidence that culture-based techniques can create cellular products that are safe and efficacious, although without Phase III data to definitively support their routine application and the difficulty of satisfying GMP standards.
机译：简介：巨细胞病毒（CMV）仍然是免疫受损患者发病和死亡的重要原因，尤其是在异基因造血移植后。导致这种风险增加的主要因素之一是T细胞免疫力下降。研究范围：在最近的综述中，我们评估了预防和先发性CMV的治疗策略，特别是在与高风险相关的情况下异基因造血移植后的患者人群。这篇评论是对我们上一篇文章的重点更新，并且对自那时以来药物，疫苗和过继性T细胞疗法的发展进行了更详细的分析。相关研究选自PubMed和Clinicaltrials.gov。检索词包括同种异体移植，巨细胞病毒，多药耐药性病毒和过继性T细胞疗法。专家意见：当前评估CMV药理学药物的随机对照研究应告知这些药物是否可提供重大的临床益处。过继细胞疗法为缺乏CMV特异性免疫力的问题提供了一种更生理的方法。最近的报告增加了证据，即基于文化的技术可以创建安全有效的细胞产品，尽管没有第三阶段的数据来明确支持其常规应用和满足GMP标准的困难。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号